Host cell protein impurities modify the immunomodulatory profile of pregnancy-specific glycoprotein 9, a cautionary tale
4 affiliations
- 1Office of Pharmaceutical Quality Research, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, U.S. Food and Drug Administration
- 2National Institute on Deafness and Other Communication Disorders (NIH), Section on Sensory Physiology and Biophysics
- 3Uniformed Services University of the Health Sciences, Pathology
- 4Facility for Biotechnology Resources, Center for Biologics Evaluation and Research, Food and Drug Administration
Abstract
Introduction: Pregnancy-specific glycoprotein 9 (PSG9) is one of 10 members of a conserved glycoprotein family within the carcinoembryonic antigen superfamily expressed by placental trophoblasts and secreted into maternal circulation. PSG1 and PSG9 induce the conversion of naïve T cells into regulatory T cells by increasing active transforming growth factor-beta (TGF-β) availability and were predicted to share anti-inflammatory activity in innate immune cells. However, while maternal PSG1 concentrations are lower in preeclampsia, PSG9 levels are reported to be elevated, suggesting PSG1 and PSG9 may differ in some immune-regulatory functions. Here, we characterized the immunomodulatory effects of PSG9 on myeloid cells.
Methods: Recombinant PSG9 was produced in Chinese hamster ovary (CHO) cells using standard expression protocols and evaluated for biological activity in human and murine myeloid cells.
Results: Results: Recombinant PSG9 preparations initially displayed batch-dependent variability, with some preparations eliciting Toll-like receptor 2 (TLR2)-mediated immunostimulatory responses in monocytes and macrophages, while others exhibited anti-inflammatory effects. Label-free quantitative proteomics revealed that pro-inflammatory preparations contained CHO host cell proteins (HCPs). Further purification by cation exchange chromatography (CIEX) substantially removed these immunomodulatory impurities, resolving batch-to-batch variations.
Discussion: These findings demonstrate that, like PSG1, fully purified PSG9 exerts anti-inflammatory activity in myeloid cells. Furthermore, process-related impurities such as HCPs can significantly confound the observed bioactivity of recombinant proteins, highlighting the critical need for rigorous impurity control during functional characterization.
Related
- The Dystrophin Glycoprotein Complex Regulates the Epigenetic Activation of Muscle Stem Cell Commitment
- The cysteine-rich domain of SEP15, a selenoprotein co-chaperone of the ER chaperone, UDP-glucose:glycoprotein glucosyltransferase, adopts a novel fold
- Regulation of Intestinal P-Glycoprotein by Gamma-Ray Irradiation: Impacts on Transporter Expression and Oxidative Stress
- The Cytosolic Zinc Finger Domain Structure of the CCHFV Glycoprotein n Is Maintained in Its Membrane-Bound Form
- Immunomodulatory Effects of the Calcitriol Analog Paricalcitol
BibTeX
@article{mendoza2026host,
title = {{Host cell protein impurities modify the immunomodulatory profile of pregnancy-specific glycoprotein 9, a cautionary tale}},
author = {Mirian Mendoza and Uriel Ortega-Rodriguez and Ha-Na Lee and Angela Ballesteros and James Warren and Maria Rendon-Correa and Wells W. Wu and Daniela Verthelyi and Gabriela Dveksler},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1882381},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1882381/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Host cell protein impurities modify the immunomodulatory profile of pregnancy-specific glycoprotein 9, a cautionary tale
AU - Mirian Mendoza
AU - Uriel Ortega-Rodriguez
AU - Ha-Na Lee
AU - Angela Ballesteros
AU - James Warren
AU - Maria Rendon-Correa
AU - Wells W. Wu
AU - Daniela Verthelyi
AU - Gabriela Dveksler
PY - 2026
DA - 2026/10/14
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1882381
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1882381/full
AB - Introduction: Pregnancy-specific glycoprotein 9 (PSG9) is one of 10 members of a conserved glycoprotein family within the carcinoembryonic antigen superfamily expressed by placental trophoblasts and secreted into maternal circulation. PSG1 and PSG9 induce the conversion of naïve T cells into regulatory T cells by increasing active transforming growth factor-beta (TGF-β) availability and were predicted to share anti-inflammatory activity in innate immune cells. However, while maternal PSG1 concentrations are lower in preeclampsia, PSG9 levels are reported to be elevated, suggesting PSG1 and PSG9 may differ in some immune-regulatory functions. Here, we characterized the immunomodulatory effects of PSG9 on myeloid cells. Methods: Recombinant PSG9 was produced in Chinese hamster ovary (CHO) cells using standard expression protocols and evaluated for biological activity in human and murine myeloid cells. Results: Results: Recombinant PSG9 preparations initially displayed batch-dependent variability, with some preparations eliciting Toll-like receptor 2 (TLR2)-mediated immunostimulatory responses in monocytes and macrophages, while others exhibited anti-inflammatory effects. Label-free quantitative proteomics revealed that pro-inflammatory preparations contained CHO host cell proteins (HCPs). Further purification by cation exchange chromatography (CIEX) substantially removed these immunomodulatory impurities, resolving batch-to-batch variations. Discussion: These findings demonstrate that, like PSG1, fully purified PSG9 exerts anti-inflammatory activity in myeloid cells. Furthermore, process-related impurities such as HCPs can significantly confound the observed bioactivity of recombinant proteins, highlighting the critical need for rigorous impurity control during functional characterization.
SN - 1664-3224
ER -